{
    "clinical_study": {
        "@rank": "23280", 
        "acronym": "A-TRI-WEEK", 
        "arm_group": [
            {
                "arm_group_label": "ATRIPLA  three times a week.", 
                "arm_group_type": "Experimental", 
                "description": "Atripla (600 mg/200 mg/245 mg) three times a week."
            }, 
            {
                "arm_group_label": "ATRIPLA one time a day.", 
                "arm_group_type": "Active Comparator", 
                "description": "Atripla (600 mg/200 mg/245 mg) one time a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective is to determine the feasibility of maintaining virologic suppression on\n      standard plasma viral load by dose reduction of ATRIPLA \u00ae."
        }, 
        "brief_title": "Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "detailed_description": {
            "textblock": "The main objective of this study is to determine the feasibility of maintaining virologic\n      suppression on standard plasma viral load (limit of detection 37 copies / mL) of a dose\n      reduction strategy of ATRIPLA \u00ae once a day to three tablets per week in patients infected\n      with HIV-1 with sustained suppression of plasma viral load standard for more than two years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (\u2265 18 years)\n\n          -  HIV-1 infection, clinical stability, and treatment with ATRIPLA \u00ae for the past two\n             years.\n\n          -  Standard plasma viral load below the limit of detection for at least 2 years.\n\n          -  CD4 count above 350/mm3 at the time of the consideration for the study.\n\n          -  Negative pregnancy test in women of childbearing age, and commitment acceptable\n             contraceptive use for at least 2 weeks before day 1 and until at least 6 months after\n             the last dose of study drug.\n\n          -  Patients should be given written informed consent\n\n          -  In the opinion of the investigator, be able to follow the design of the protocol\n             visits\n\n        Exclusion Criteria:\n\n          -  Patients who have experienced virologic failure prior to any antiretroviral regimen\n\n          -  Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine\n\n          -  Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months\n             prior to entry of the patient in the study\n\n          -  Any contraindication to study drug\n\n          -  Any condition not ensure proper adherence to the study at the discretion of the\n             attending physician of the patient\n\n          -  Uncontrolled preexisting psychiatric illness\n\n          -  Any current sign of alcoholism or other drug use."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778413", 
            "org_study_id": "A-TRI-WEEK"
        }, 
        "intervention": {
            "arm_group_label": [
                "ATRIPLA  three times a week.", 
                "ATRIPLA one time a day."
            ], 
            "intervention_name": "ATRIPLA", 
            "intervention_type": "Drug", 
            "other_name": [
                "efavirenz/emtricitabine/tenofovir disoproxil fumarate 600 mg/200", 
                "mg/245 mg"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Efavirenz", 
                "Efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2013", 
        "location": {
            "contact": {
                "email": "acruceta@clinic.ub.es", 
                "last_name": "Anna Cruceta, MD", 
                "phone": "0034932275400", 
                "phone_ext": "4380"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Hospital Clinic i Provincial Barcelona"
            }, 
            "investigator": {
                "last_name": "Esteban Martinez, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine", 
        "overall_contact": {
            "email": "acruceta@clinic.ub.es", 
            "last_name": "Anna Cruceta, MD", 
            "phone": "932275400", 
            "phone_ext": "4380"
        }, 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednic i Provincial de Barcelona", 
            "last_name": "Esteban Martinez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients who continue with a standard plasma viral load (<37 copies / mL) at 24 weeks by intention to treat analysis.", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778413"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3 Cl\u00ednic per la Recerca Biom\u00e8dica", 
            "investigator_full_name": "Anna Cruceta", 
            "investigator_title": "Project manager", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of patients with ultrasensitive viral load (<1 copy / mL) after 24 weeks.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "The change from baseline to 24 weeks in the viral reservoir in peripheral blood mononuclear cells", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "description": "Changes from baseline to 24 weeks in the production of TRECs, the immunological profile of activation (CD38 and HLA-DR) and senescence (CD57 and CD28) in CD4 and CD8 lineages in the proportions of naive T cells effector and memory (CCR7 and CD45RA), and changes in the levels of apoptosis in vitro by staining with annexin V.", 
                "measure": "Immunological", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "measure": "Changes in plasma levels of efavirenz.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "measure": "Changes in sleep quality (Pittsburgh Sleep Quality Index).", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "measure": "General Safety (report adverse events, serious adverse events and treatment discontinuation due to adverse events)", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Changes in plasma levels of vitamin D.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "measure": "Changes in lipid profile.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "measure": "Changes in estimated glomerular filtration rate.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }
        ], 
        "source": "Fundacion Clinic per a la Recerca Biom\u00e9dica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anna Cruceta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}